Tumor budding correlates with the protumor immune microenvironment and is an independent prognostic factor for recurrence of stage i lung adenocarcinoma

Chest

Volumn 148, Issue 3, 2015, Pages 711-721

  Kadota, Kyuichi ^a,b   Yeh, Yi Chen ^a   Villena Vargas, Jonathan ^a   Cherkassky, Leonid ^a   Drill, Esther N ^a   Sima, Camelia S ^a   Jones, David R ^a   Travis, William D ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD68 ANTIGEN; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3; CD3 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; IL12RB2 PROTEIN, HUMAN; INTERLEUKIN 12 RECEPTOR; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ACINAR CELL CARCINOMA; ADULT; AGED; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CELL INTERACTION; COHORT ANALYSIS; COLLOID CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR BUDDING; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VALIDATION PROCESS; ADENOCARCINOMA; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, INTERLEUKIN-12; RECEPTORS, INTERLEUKIN-7; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84940111608     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-3005     Document Type: Conference Paper

References (46)

1. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female diff erences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005; 117 ( 2): 294-299.
2. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. US lung cancer trends by histologic type. Cancer. 2014; 120 ( 18): 2883-2892.
3. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 ( 5): 395-409.
4. National Lung Screening Trial Research Team, Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011; 258 ( 1): 243-253.
5. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007; 120 ( 4): 868-874.
6. Goldstraw P, Crowley J, Chansky K, et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifi cation of malignant tumours. J Thorac Oncol. 2007; 2 ( 8): 706-714.
7. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classifi cation of lung adenocarcinoma. J Thorac Oncol. 2011; 6 ( 2): 244-285.
8. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classifi cation of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol. 2011; 24 ( 5): 653-664.
9. Yoshizawa A, Sumiyoshi S, Sonobe M, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classifi cation for prognosis and association with EGFR and KRAS gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol. 2013; 8 ( 1): 52-61.
10. Warth A, Muley T, Meister M, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classifi cation system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012; 30 ( 13): 1438-1446.
11. Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013; 81 ( 3): 371-376.
12. Mansuet-Lupo A, Bobbio A, Blons H, et al. The new histologic classifi cation of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifi es tumors with diff erent mutation status: The experience of a French cohort. Chest. 2014; 146 ( 3): 633-643.
13. Karamitopoulou E, Zlobec I, Kölzer V, et al. Proposal for a 10-high-power-fi elds scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol. 2013; 26 ( 2): 295-301.
14. Mitrovic B, Schaeff er DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol. 2012; 25 ( 10): 1315-1325.
15. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119 ( 6): 1420-1428.
16. Taira T, Ishii G, Nagai K, et al. Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. L ung Cancer. 2012; 76 ( 3): 423-430.
17. Yamaguchi Y, Ishii G, Kojima M, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: Tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol. 2010; 5 ( 9): 1361-1368.
18. Koga K, Hamasaki M, Kato F, et al. Association of c-Met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma. Lung Cancer. 2013; 82 ( 3): 413-419.
19. Santisteban M, Reiman JM, Asiedu MK, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009; 69 ( 7): 2887-2895.
20. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/ TNF(alpha)-mediated epithelialmesenchymal transition generates breast cancer stem cells with a claudinlow phenotype. Cancer Res. 2011; 71 ( 13): 4707-4719.
21. Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelialmesenchymal transition and generation of breast cancer stem cells. Cancer Res. 2010; 70 ( 8): 3005-3008.
22. Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-profi cient and-defi cient colorectal cancers. Histopathology. 2011; 59 ( 3): 482-495.
23. Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014; 25 ( 5): 605-620.
24. Helm O, Held-Feindt J, Grage-Griebenow E, et al. Tumor-associated macrophages exhibit pro-and anti-infl ammatory properties by which they impact on pancreatic tumorigenesis. Int J Cancer. 2014; 135 ( 4): 843-861.
25. Liu CY, Xu JY, Shi XY, et al. M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway. L ab Invest. 2013; 93 ( 7): 844-854.
26. Suzuki K, Kadota K, Sima CS, et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: Tumor interleukin-12 receptor b 2 (IL-12R b 2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013; 31 ( 4): 490-498.
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCIEORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol. 2005; 2 ( 8): 416-422.
28. Edge SB, Byrd DR, Compton CC, et al. American Joint Committee on Cancer Cancer Staging Manual. 7th ed. New York, NY : Springer; 2009 : 253-270.
29. Kadota K, Suzuki K, Kachala SS, et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol. 2012; 25 ( 8): 1117-1127.
30. Kadota K, Yeh YC, Sima CS, et al. The cribriform pattern identifi es a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: A conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. M od Pathol. 2014; 27 ( 5): 690-700.
31. Kadota K, Nitadori J, Sarkaria IS, et al. Th yroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classifi cation in patients with stage I lung adenocarcinoma. Cancer. 2013; 119 ( 5): 931-938.
32. Kadota K, Colovos C, Suzuki K, et al. FDGPET SUVmax combined with IASLC/ ATS/ERS histologic classifi cation improves the prognostic stratifi cation of patients with stage I lung adenocarcinoma. Ann Surg Oncol. 2012; 19 ( 11): 3598-3605.
33. Kadota K, Suzuki K, Colovos C, et al. A nuclear grading system is a strong predictor of survival in epitheloid diff use malignant pleural mesothelioma. Mod Pathol. 2012; 25 ( 2): 260-271.
34. Chappell R. Competing risk analyses: how are they diff erent and why should you care? Clin Cancer Res. 2012; 18 ( 8): 2127-2129.
35. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res. 2012; 18 ( 8): 2301-2308.
36. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16 : 1141-1154.
37. Kadota K, Yeh YC, D'Angelo SP, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol. 2014; 38 ( 8): 1118-1127.
38. Nitadori J, Bograd AJ, Kadota K, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst. 2013; 105 ( 16): 1212-1220.
39. Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3 1 regulatory T cells. Nat Rev Immunol. 2011; 11 ( 2): 119-130.
40. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res. 2011; 71 ( 22): 6915-6920.
41. Chaput N, Louafi S, Bardier A, et al. Identifi cation of CD8 1 CD25 1 Foxp3 1 suppressive T cells in colorectal cancer tissue. Gut. 2009; 58 ( 4): 520-529.
42. Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013; 43 ( 6): 1518-1528.
43. Jiang B, Mason J, Jewett A, et al. Tumorinfi ltrating immune cells: Triggers for tumor capsule disruption and tumor progression? Int J Med Sci. 2013; 10 ( 5): 475-497.
44. Man YG, Mason J, Harley R, Kim YH, Zhu K, Gardner WA. Leukocyte-mediated cell dissemination and metastasis: fi ndings from multiple types of human tumors. J Cell Biochem. 2011; 112 ( 4): 1154-1167.
45. Satoh K, Nimura S, Aoki M, et al. Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: possible involvement of c-Met. Cancer Sci. 2014; 105( 11): 1487-1495.
46. Puppa G, Senore C, Sheahan K, et al. Diagnostic reproducibility of tumour budding in colorectal cancer: A multicentre, multinational study using virtual microscopy. Histopathology. 2012; 61 ( 4): 562-575.